TABLE 3.
Safety assessment reported by volunteers within 2 months of the trial.
Symptoms | All (n = 50) | Control (n = 25) | 250 mg OPP (n = 25) | p |
---|---|---|---|---|
None reported | 7 | 5 | 2 | 0.417 |
Bloated | 1 | 0 | 1 | 1.000 |
Easy to defecate | 13 | 6 | 7 | 0.747 |
Get hungry easily | 9 | 5 | 4 | 1.000 |
Lightheaded | 4 | 2 | 2 | 1.000 |
Lose weight easily | 5 | 3 | 2 | 1.000 |
More energetic | 7 | 3 | 4 | 1.000 |
Reduce menstrual pain | 1 | 0 | 1 | 1.000 |
Short menstrual duration | 2 | 0 | 2 | 0.490 |
Sleepiness | 1 | 1 | 0 | 1.000 |
Data are tabulated as frequency, n (%).